A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial

Huei Ting Tsai, Stanley N. Caroff, Del D. Miller, Joseph Patrick McEvoy, Jeffrey A. Lieberman, Kari E. North, T. Scott Stroup, Patrick F. Sullivan

Research output: Contribution to journalArticlepeer-review

52 Scopus citations


Tardive dyskinesia (TD) is a movement disorder characterized by involuntary oro-facial, limb, and truncal movements. As a genetic basis for inter-individual variation is assumed, there have been a sizeable number of candidate gene studies. All subjects met diagnostic criteria for schizophrenia and were randomized to receive antipsychotic medications as participants in the Clinical Antipsychotic Trials of Intervention Effectiveness project (CATIE). TD was assessed via the Abnormal Involuntary Movement Scale at regular intervals. Probable TD was defined as meeting Schooler-Kane criteria at any scheduled CATIE visit (207/710 subjects, 29.2%). A total of 128 candidate genes were studied in 710 subjects-2,580 SNPs in 118 candidate genes selected from the literature (e.g., dopamine, serotonin, glutamate, andGABApathways) and composite genotypes for 10 drug -metabolizing enzymes. No single marker or haplotype association reached statistical significance after adjustment for multiple comparisons. Thus, we found no support for either novel or prior associations from the literature.

Original languageEnglish (US)
Pages (from-to)336-340
Number of pages5
JournalAmerican Journal of Medical Genetics, Part B: Neuropsychiatric Genetics
Issue number1
StatePublished - Jan 2010
Externally publishedYes


  • Adverse drug reaction
  • Antipsychotic medication
  • Candidate gene association
  • Genetic
  • Schizophrenia
  • Tardive dyskinesia

ASJC Scopus subject areas

  • Genetics(clinical)
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial'. Together they form a unique fingerprint.

Cite this